Neurology · 2024 · 13 citations · 40 references
Life SciencesNeurologyNeuroscienceDiagnostic ImagingNeurogeneticsNeuropathologyBiomarkers Of NeurodegenerationBrain ImagingCerebrospinal Fluid BiomarkersNeurodegenerative DiseasesNeurodegenerative DisordersSpinocerebellar AtaxiasAtaxia Severity ScalesHereditary AtaxiasNeurofilament Heavy ChainNeurofilament ProteinsSpinocerebellar Ataxia Type 2Spinocerebellar Ataxia Type 7Structural Brain AbnormalitiesStructural Mri
BACKGROUND AND OBJECTIVES: Brain MRI abnormalities and increases in neurofilament light chain (NfL) have mostly been observed in cross-sectional studies before ataxia onset in polyglutamine spinocerebellar ataxias. Our study aimed to identify longitudinal changes in biological, clinical, and/or imaging biomarkers in spinocerebellar ataxia (SCA) 2 and SCA7 carriers over 1 year. METHODS: We studied SCA2 and SCA7 carriers and controls (expansion-negative relatives) at the Paris Brain Institute. Inclusion criteria included Scale for the Assessment and Rating of Ataxia (SARA) scores between 0 and 15. Assessments at baseline, 6 months, and 12 months comprised neurologic, quality of life, orofacial motor, neuropsychological, and ophthalmologic examinations, along with gait and oculomotor recordings, brain MRI, CSF, and blood sampling. The primary outcome was the longitudinal change in these assessments over 1 year. RESULTS: ) volume loss and a worsening of gait assessment; in SCA7, SARA score significantly increased (+1.3 ± 0.4) and outer retinal nuclear layer thickness decreased (-15.4 ± 1.6 μm); for both SCA groups, the orofacial motor assessment significantly worsened. For preataxic and early ataxic carriers, the strongest longitudinal deterioration on outcome measures was orofacial motility in SCA2 and retinal thickness in SCA7. DISCUSSION: Despite the limitation of the small sample size, we detected annual changes in preataxic and early ataxic SCA individuals across brain MRI imaging, clinical scores, gait parameters, and retinal thickness. These parameters could serve as potential end points for future therapeutic trials in the preataxic phase. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov NCT04288128.
40
Scale for the assessment and rating of ataxia
T. Schmitz-Hübsch, Sophie Tézenas du Montcel, L. Baliko et al. · Neurology · 2006 · 2K citations · Full text
Sarah J. Tabrizi, Rachael I. Scahill, Gail Owen et al. · The Lancet Neurology · 2013 · 839 citations
The cerebellar cognitive affective/Schmahmann syndrome scale
Franziska Hoche, Xavier Guell, Márk Vangel et al. · Brain · 2017 · 474 citations · Full text
Medicine, Neurology, Neuroscience +17